Annual report pursuant to Section 13 and 15(d)

Schedule of Stock Options Issued and Outstanding Activities (Details)

v3.22.4
Schedule of Stock Options Issued and Outstanding Activities (Details) - 2028 Equity Plan [Member] - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Stock Options, Outstanding Stock Options Beginning 1,419,242 1,399,242
Weighted Average Exercise Price, Weighted Average Grant Date Fair Value, Outstanding Stock Options Beginning $ 0.73 $ 0.61
Remaining Contractual Term (Years), Outstanding Stock Options Ending 8 years 3 months 18 days [1] 8 years
Outstanding Stock Options, intrinsic value beginning [2] $ 6,665
Number of Stock Options, Granted [3] 2,365,000 20,000
Weighted Average Exercise Price, Granted [3] $ 3.68 $ 9.08
Number of Stock Options, Exercised (965,341)
Weighted Average Exercise Price, Exercised $ 0.72
Number of Stock Options, Forfeited (253,524)
Weighted Average Exercise Price, Forfeited $ 3.83
Remaining Contractual Term (Years), Outstanding Stock Options Beginning 7 years  
Number of Stock Options, Outstanding Stock Options Ending 2,565,377 [1] 1,419,242
Number of Stock Options, Outstanding Stock Options Ending $ 3.14 [1] $ 0.73
Outstanding Stock Options, intrinsic value ending [2] $ 428 [1] $ 6,665
Number of Stock Options, Vested and exercisable stock options 1,119,006  
Weighted Average Exercise Price, Vested and exercisable stock options $ 2.53  
Remaining Contractual Term (Years), Vested and Exercisable 7 years 1 month 6 days  
Vested and Exercisable Stock Options, intrinsic value [2] $ 428  
[1] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan, as of December 31, 2022 and December 31, 2021.
[2] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics Inc. common stock on each of December 31, 2022 and December 31, 2021 and the exercise price of the underlying Lucid Diagnostics Inc. stock options, to the extent such quoted price is greater than the exercise price.
[3] Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.